Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P van Meerbeeck

Showing results (181-190 of 250) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Acta Chirurgica Belgica|April 13, 2017
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year periodAndreas Domen, Christophe De Laet, Wies Vanderbruggen, et al.
Journal of Biomedical Optics|December 1, 2004
Raman microspectroscopic mapping studies of human bronchial tissueSenada Koljenović, Tom C Bakker Schut, Jan P van Meerbeeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2010
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancerS Senan, F Cardenal, J Vansteenkiste, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2011
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort studyKevin Hollevoet, Joris Van Cleemput, Joël Thimpont, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experienceRobert C Rintoul, Kurt G Tournoy, Hesham El Daly, et al.
Clinical Chemistry|May 2, 2009
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serumKevin Hollevoet, Dirk Bernard, Frank De Geeter, et al.
ERJ Open Research|February 18, 2026
Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysisKathleen Zwijsen, Reinier R L Wener, Ellen Heirwegh, et al.
Tobacco Prevention & Cessation|March 2, 2022
Lung cancer in Europe: The way forwardMonica Racovita, Eleanor Wheeler, Suzanne Wait, et al.
Chest|July 9, 2011
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factorKevin Hollevoet, Kristiaan Nackaerts, Olivier Thas, et al.
Pageof 25

Showing results (181-190 of 250) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Acta Chirurgica Belgica|April 13, 2017
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year periodAndreas Domen, Christophe De Laet, Wies Vanderbruggen, et al.
Journal of Biomedical Optics|December 1, 2004
Raman microspectroscopic mapping studies of human bronchial tissueSenada Koljenović, Tom C Bakker Schut, Jan P van Meerbeeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2010
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancerS Senan, F Cardenal, J Vansteenkiste, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2011
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort studyKevin Hollevoet, Joris Van Cleemput, Joël Thimpont, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experienceRobert C Rintoul, Kurt G Tournoy, Hesham El Daly, et al.
Clinical Chemistry|May 2, 2009
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serumKevin Hollevoet, Dirk Bernard, Frank De Geeter, et al.
ERJ Open Research|February 18, 2026
Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysisKathleen Zwijsen, Reinier R L Wener, Ellen Heirwegh, et al.
Tobacco Prevention & Cessation|March 2, 2022
Lung cancer in Europe: The way forwardMonica Racovita, Eleanor Wheeler, Suzanne Wait, et al.
Chest|July 9, 2011
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factorKevin Hollevoet, Kristiaan Nackaerts, Olivier Thas, et al.
Pageof 25